This overly restrictive policy will unnecessarily limit vaccine access for people who want protection, potentially leaving millions of healthy Americans vulnerable. The extensive safety and effectiveness data already collected from hundreds of millions of doses should be sufficient, and requiring new placebo-controlled trials raises ethical concerns given COVID-19's continued threat of hospitalization and death.

ThereThe isnew framework represents a 34%balanced, chanceevidence-based approach that thereensures willtimely beaccess twofor orvulnerable morepopulations COVIDwhile demanding rigorous scientific proof of benefit for low-19risk hospitalizationindividuals. wavesThis inpolicy theshift Unitedwill Stateshelp restore public trust in atvaccines leastby requiring gold-standard data and acknowledging that a one-size-fits-all ofapproach themay 2028no andlonger 2029be respiratoryappropriate diseasegiven seasons,widespread accordingimmunity tofrom theprior Metaculusvaccination predictionand communityinfection.

This overly restrictive policy will unnecessarily limit vaccine access for people who want protection, potentially leaving millions of healthy Americans vulnerable. The extensive safety and effectiveness data already collected from hundreds of millions of doses should be sufficient, and requiring new placebo-controlled trials raises ethical concerns given COVID-19's continued threat of hospitalization and death.